[Temporary approval for intranasal naloxone: Setting up in a French addiction center]. / Pratique de l'ATU de cohorte de la naloxone intranasale (Nalscue®) : mise en place dans un CSAPA parisien.
Therapie
; 73(6): 495-500, 2018 Dec.
Article
en Fr
| MEDLINE
| ID: mdl-29680374
Intranasal naloxone aims at preventing opioid overdose related deaths in active drug users. In France, it has been available since July 2016 through a temporary approval which requires a hospital-based pharmacy and a nominative registration of each patient. We present the characteristics of the first patients who could receive this prescription in our hospital-based addiction center and how they used naloxone during follow-up. Results favor a larger dispensing of naloxone. Patients' as well as peers' and families' education is needed.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Aprobación de Drogas
/
Sobredosis de Droga
/
Instituciones de Atención Ambulatoria
/
Medicina de las Adicciones
/
Implementación de Plan de Salud
/
Naloxona
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
/
Sysrev_observational_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
Fr
Revista:
Therapie
Año:
2018
Tipo del documento:
Article